TY  - JOUR
T1  - Karaciğerde Detoksifikasyon
TT  - Detoxification  in  Liver
AU  - Dıraman, Emine
PY  - 2021
DA  - December
DO  - 10.31590/ejosat.1049025
JF  - Avrupa Bilim ve Teknoloji Dergisi
JO  - EJOSAT
PB  - Osman SAĞDIÇ
WT  - DergiPark
SN  - 2148-2683
SP  - 1156
EP  - 1161
IS  - 32
LA  - tr
AB  - Karaciğer, hayatın devamı için birçok fizyolojik ve biyokimyasal olayın meydana geldiği yerdir. Karaciğer içerisinde bir seri kompleks tepkime gerçekleşir ve zararlı rnaddeleri zehirsizleştirir. Bu olaya detoksifikasyon denir. Detoksifikasyon faz I ve faz II olarak iki basamakta gerçekleşir. Bu derlemede; karaciğerin detoksifikasyonunda etkili olan enzimler ve bu enzimlerin genlerle ilişkisi, inhibisyonu, indüksiyonu  ve detoksifikasyonunun  besinlerle etkileşimi araştırılarak sunulmuştur.
KW  - Antioksidant
KW  - CytP450
KW  - detoksifikasyon
KW  - karaciğer
N2  - The liver is where physological and biochemical events occur for living.  A series of complex chemical reaction occurs and detoxifies harmful substances in the liver. This event is called "detoxification". It realizes in two stages as phase I and phase II. It's represented by researching enzymes which effect liver detoxification and relevent with genes,  inhibition, induction and effection with nutrients.
CR  - Appelt, L.C. (1997).  Soyfeeding Induces Phase II Enzymes in Rat    Tissues,   Nutr. Rev. 55:398- 400.
CR  - Bandman, V.J. ve Holmans, P. (1997). Association of Slow      Aceytylator Genotype for  N-acetyletransferase 2 with Familial     Parkinson's   Disease.   Lancet,  350, 1136-1139.
CR  - Barch, D.H., ve Rundhaugen., L. (1994). Ellagic Acid Induces     NADPH: Quinone Reductase Trough Activation of the Antioxidant    Responsive  Element of the Rat NADPH: Quinone Reductase Gene, Carcinogenesis,    15:2065-2068.
CR  - Benet, L.Z., Kroetz, D.L. ve Sheiner, L.B. (1996). Pharmacokinetics:    The  Dynamics of Drug Absorbtion, Distrubution and Elemination, In:    Molinoff, P.B, Ruddon, R.W. Goodman Gilman A, eds. The Pharmacological Basis of Therapeutics. 9. Baskı, NewYork,   NY: Mc
CR  - Blakeslee, D. (1998).  The Cytochrome P450 Enzyme Systems. A Backround Briefing,  American Medical Association.  Graw, 3 -27 6.Bohinski, R.C.  (1987). Modern Concepts in Biochemistry, Fifth edition, Allyn and Bacon,  Inc.
CR  - Curley, R.W., Humphries K..A., Koolemans-Beyna, A., Abou
   Issa, H.ve Webb, T.E. (1994). Activity of D-Glucarate Analogues: Synergistic Antiproliferative Effects with Retinoid in Cultured Human Mammary Tümör Cells Appear to Specifically Require the D-Glucarate Stracture, Life Sci, 54(18), 1299-303.
CR  - Daly AK., Cholerton, S., Gregory, W. ve Idle, J.R. (1993).    Metabolic Polimorplıisms, .Pharmac Ther, 57(2-3):129-60.
CR  - Darley-Usmar, V. ve Halliwell, B. (1989). Blood Radicals:    Reactive oxygen species, reactive nitrogen species, transition metal ions and the vascular system. Pharm.  Res, 13, 649-662
CR  - Feldman, EB. (1997). How Grapefruit Juice Potantiates Drug
   Bioavailabity. Nutr. Rev., 55:398-400.
CR  - Gamble, S. C., Wiseman A. ve Goldfarbb, P.S. (1997).    Selenium Dependent Glutathione Peroxidase and Other Selenoproteins: Their Synthesis and Biochemical Roles.    J.Chem. Tech. Biothechnol, 68, 123-134.
CR  - Ghosheh, O. ve Hawes, E.M.. (2002). N-glucuronidation of     Nicotine and Cotinine in Human: Formation of Cotinine     Glucuronide in Liver Microsomes and Lack of Catalysis by 10    examined UDP Glucuronosyltransferases., Drug. Metab.    Dispos. Sep, 30,9, 991 -996.
CR  - Gözükara, E. M., (2001). Biyokimya, Cilt 2, 4.Baskı, Nobel Kitabevleri
CR  - Guengerich F.P.,(1984). Effects of Nutritive Factors on Metabolic Processes Involving Bioactivation and Detoxification of Chenıicals,      Ann. Rev .Nutr., 4, 207-231.
CR  - Gutteridge, J.M. ve Halliwell, B. (2000).  Free radicals and antioxidants in the year 2000 a historical look to the future.   Ann. N.  Y.  Acad. Sci. Review,  899, 136-47.
CR  - Halliwell, B. ve Gutteridge, J. M.  (1989). Free radicals in biology
    and medicine. Clarendon Press Oxford. UK,  Clarendon press
CR  - Halliwell, B. ve Anımoa, O. I. (1991). DNA damage by oxygen
      drived species. Its mechanisms and measurement in mammalian
     species.  FEBS Lett., 281, 9-19.
CR  - He, Z.X., Chen, X.W., Zhou, Z.W., Zhou, S.F. (2015).      “Impact of physiological, pathological and environmental      factors on the expression and activity of human cytochrome     P450 2D6 and implications in precision medicine”, Drug     Metab Rev., 1–50.
CR  - Iafbovici, D. (1997).  Single Blood Test might Predict Drug’s Effects on Patients. J NIH Res; 9,34-45.
CR  - Kall, M.A. ve Clausen J. (1995). Dietary effect on mixed function P4501A2 activity assayed by estimation of caffeine metabolism in man, Hum. Exp. Toxicol. 14, 801–807.
CR  - Kumar, G.N., Rodrigues, A.D., Buko, A.M., ve Denissen, J.F.       (1996). Cyt P450 Mediated Metabolism of the HIV-1Protease Inhibitor Ritonavir in Human Liver Microsomes, J. Pham. Exp.       Therapeutics, 277 (l);423-431.
CR  - Lehninger A.L. (1982). Principles of Biochemistry. The Johns Hopkins University School of Medicine,  Worth Publishers,  İnc. 12
CR  - Liska, D.J. (1998). The detoxification enzyme systems.   Altern.  Med.                Rev, 3:3, 187-198.
CR  - Manson, M.M., Ball, H.V.L., Barret, M.C.,Clark H.L., Judah D.J.,               Williamson G. ve Neal G.E. (1997).  Mechanismof Action of Dietaty Chemoprotective Agents in Rat Liver: Induction of Phase I and Phase II Drug Metabolising Enzymes and Aflatoxin Bl Metabolism, Carcinogenesis, 18, 1729-1738
CR  - Mathews, C.K., Vanholde, K.E.V ve  Aham, K.G. (2000).  Biochemistry,3.ed,Longman Inc.
CR  - Maxwell, R.J.S. (1991).  Prospects  for the use of antioxdiants therapies. Drugs,  49:3, 345-361.
CR  - Meyer, U.A., Zanger, U.M., Skoda, R.C., Grant D. ve  Blum M. (1990).  Genetic Polymorphisms of Drug Metabolism. Prog Liver Dis., 9, 307-323.
CR  - Miehiels,  C.,  Raes, M., Toussaint. & Ramacle, J. (1994). Importance of Se-GPX, Catalase and Cu-Zn-SOD for Cell Survival Against, Additative stres.  Free rad. Biol. Med. 17, 235-248.
CR  - Milne,  B.D. (1999).  Trace Elements.  In: Burtis, C.A. ve  Aslwood, E.R.  Eds. Tietz.  Text Book of Clinical Chemistry.  W.B. Founders Company 3.Baskı, Phyladelphia, 1043-1044.
CR  - Pantuck, E.J., Pantuck C.B., Garland W. A., Min B.H.,Wattenberg L.W., Anderson K…Conney A. (1979). Stimulatory Effect of Brussels Sprouts and Cabbage on Human Drug Metabolism., Clin. Pharm. Ther., 25, 88-95.
CR  - Park, B.K., Kıtterıngham N.R., Pırmohamed M. ve Tucker G.T. (1996). Relevance of Induction of Human Drug-Metabolizing Enzymes: Pharmacological and Toxicological Implications. Br J. Clin. Pharmacol, 41, 477-491.
CR  - Rannug,A., Alexandrie, A.K., Persson, I. ve Ingelman-Sundberg M. (1995). Genetic   Polymorphism   of   CytP450    lAl, D6,  E1, Regulation   and Toxicological Significance  J. Occupational Environ., Med, 37;25-36.
CR  - Rebbeck, T.R. (1997). Molecıılar Epidemiology of the Human Glutathione S-Transferase Genotypes GSTM1 and GSTT1 in Cancer Susceptibility, Cancer Epidemiology, Biomarkers &Prevention,6(9),733-743.
CR  - Schubert,W., Cuilberg, G, Edgar, B. ve  Hedner, T. (1994). Inhibition of 17B-Estradiol Metabolism by Grapefruit Juice in Ovariectomised Woman. Matııritas, 20:155-163.
CR  - Sheriock, S. (2011). Diseases of the liver and biliary system.  Blockwell Scientific Publications,  12. Baskı.
CR  - Ulugöl, A., Karadağ, H., Dökmeci, D., Gündüz, Ö., Topuz, R. D. (2017). Farmakoloji, Nobel Tip Kitapevleri, İstanbul. 2017.
CR  - Wacher,V.J., Wu, C.Y. ve Benet, L.Z. (1995). Overlapping Substrate       Specifities and Tissue Distribution of cytP450 3A and P-Glycoprotein: Implications for Drug Delivery and Activity in Cancer Chemotheıaphy, Mol Carcinog,13, 129-134
CR  - Vermeulen, N.P.E. (1996). Role of Metabolism in Chemical Toxicity, In:Ioannides, C.,ed., CytP450: Metabolic and Toxicological Aspects, Boca Raton, FL: CRC press,  Inc, 29-53.
CR  - Weaver, R.J., Blomme, E.A., Chadwick, A.E., Copple, I.M.,
    Gerets,.H.H.J., Goldring, C.E., Guillouzo, A. ve  Park,  B.K.
     (2020).  Managing the challenge of drug-induced liver injury: a
  roadmap for the development and deployment of preclinical
    predictive models. Nat. Rev. Drug. Discov., 19,131–148.
CR  - Wickramage, I., Tennekoon, K.H., Ariyaratne, M.A.Y., Hewage, A.S. ve  Sundralingam, H. (2017). “CYP2D6  polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study”, Breast Cancer - Targets and Therapy, 9:111-120.
UR  - https://doi.org/10.31590/ejosat.1049025
L1  - https://dergipark.org.tr/tr/download/article-file/2160698
ER  -